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INTRODUCTION
Neuroblastoma (NB) is the most common extracranial 
solid tumor in children. Although the prognosis of low- 
and intermediate-risk NB with conventional treatment 
modalities is excellent, the prognosis of high-risk NB with 
conventional treatment alone is very poor. The current 
standard treatment for high-risk NB consists of induction 
treatment (conventional chemotherapy and surgery with 
or without local radiotherapy), high-dose chemotherapy and 
autologous stem cell transplantation (HDCT/autoSCT) as 
a consolidation treatment, and 13-cis-retinoid acid to reduce 
relapse from minimal residual disease. However, the event- 
free survival rates are only 30-40%, which is unsatisfactory. 
For this reason, a few clinical trials of tandem HDCT/ 
autoSCT, high-dose 
131I-meta-iodobenzylguanidine (MIBG) 
treatment incorporated into HDCT/autoSCT, and anti-GD2 
treatment after HDCT/autoSCT, are currently underway to 
improve the survival of high-risk NB patients. Furthermore, 
because about half of high-risk NB patients still die from 
treatment failure, allogeneic SCT (alloSCT) is being in-
vestigated as a potential curative option.
AlloSCT AFTER RELAPSE
Conventional chemotherapy is ineffective in patients who 
failed treatment, and they cannot tolerate additional in-
tensive treatment because they have previously received 
intensive treatment. Therefore, in these patients, there is 
no realistic chance for cure using conventional treatment 
options alone. For this reason, alloSCT is being investigated 
as a potential curative treatment option, because it offers 
a graft-versus-tumor (GVT) effect not observed in autoSCT. 
Although a GVT effect has been demonstrated in patients 
w i t h  a d v a n c e d  N B  w h o  r e c e i v e d  a l l o S C T  [ 1 ] ,  r e g i m e n -  
related mortality following standard alloSCT with an inten-
sive myeloablative conditioning regimen may be extremely 
high in patients who have already been heavily treated.
REDUCED-INTENSITY AlloSCT
In recent years, several groups of investigators have 
developed reduced-intensity conditioning regimens that 
lead to engraftment of donor lymphoid and hematopoietic 
stem cells without the extra-hematopoietic toxicities of 
standard myeloablative conditioning, while conserving the 
graft-versus-leukemia (GVL) or GVT effect. The reduced 
regimen-related toxicity may make reduced-intensity 
alloSCT (RI alloSCT) particularly suitable for patients at 
high-risk of regimen-related mortality, especially previous 
HDCT/autoSCT recipients. In adults, striking GVT effects 
after RI alloSCT have been described in refractory breast 
cancer and renal cell carcinoma [2]. Currently, the number 
of studies employing RI alloSCT for NB is very small. 
However, early studies have suggested that it is a feasible 
approach and have shown GVT effects, which were 
confirmed by tumor disappearance after induction of acute 
graft-versus-host disease (GVHD) through withdrawal of 
immunosuppressive drugs or donor leukocyte infusion. 
However, control of GVHD using immunosuppressive drugs 
caused NB reappearance. The GVT effect could not control 
tumor proliferation, particularly in patients with a signi-
ficant tumor burden at transplantation. Furthermore, it is Korean J Hematol 2012;47:3-5.
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Fig. 1. Representative case. The 
patient had 
131I-meta-iodobenzy-
lguanidine (MIBG) uptake at re-
lapse after tandem HDCT/auto-
SCT (A) (arrow head). He still had 
MIBG uptake arrows after con-
ventional salvage treatment (B) 
(arrow head). RI alloSCT was given 
after high-dose 
131I-MIBG treat-
ment (18 mCi/kg). Regimen-re-
lated toxicity was minimal and 
rapid engraftment and complete 
donor chimerism were success-
fully achieved. Grade I acute graft- 
versus-host disease (GVHD) de-
veloped after withdrawal of im-
mune suppression, and he had a 
moderate chronic GVHD. MIBG 
uptake was absent from day 90 
and day 180 evaluations (C and D).
difficult to effectively reduce the tumor burden prior to 
transplantation using conventional treatment modalities. 
Therefore, a new treatment modality to effectively reduce 
tumor burden prior to transplantation, as well as a post- 
transplant adjuvant treatment to increase the GVT effect 
are needed to improve the outcome after RI alloSCT. 
REDUCTION OF TUMOR BURDEN PRIOR TO RI 
AlloSCT
Because the GVT effect was not sufficient to prevent tumor 
progression in patients with significant tumor burdens, to 
effectively reduce tumor burden prior to transplantation, a 
new treatment modality is needed to improve the outcome 
after RI alloSCT. Unfortunately, an effective salvage regimen 
after relapse is not yet available. However, high-dose 
131I-MIBG treatment might be an option for efficient 
reduction of tumor burden prior to RI alloSCT, because it 
has no significant toxicity other than hematologic toxicity, 
which can be overcome by alloSCT. Since investigators have 
successfully incorporated high-dose 
131I-MIBG treatment into 
HDCT/autoSCT, a few investigators have begun to incor-
porate high-dose 
131I-MIBG treatment into RI alloSCT and 
have shown that it is a feasible approach (Fig. 1) [3, 4].
STEM CELL SOURCE
Stem cell source is also an important issue to enhance 
the GVT effect. For many years, HLA-matched donors were 
the only types of donor routinely employed; however, 
recently, mismatched SCT was also shown to be feasible. 
Stronger GVHD and possibly stronger GVT effects are 
expected in unrelated or mismatched SCT than in related 
or matched SCT. Therefore, unrelated or mismatched SCT 
might be a preferred option, and not an alternative to related 
or matched SCT in specific subpopulations of patients, such 
as those with recurrent NB. Killer cell immunoglobulin-like 
receptor (KIR) ligand-mismatched SCT is also a possible 
option to enhance the GVT effect in NB, because NB cells 
do not express HLA class I antigens; therefore, NB cells 
could be an excellent target f o r  N K  c e l l  a l l o i m m u n i t y .
POST-SCT ADJUVANT TREATMENT
Post-SCT adjuvant treatment might be another approach 
to increase the GVT effect. Donor leukocyte or NK cell 
infusion, NB-specific antibody treatment, or cytokine 
treatment after SCT might be options for enhancing the 
GVT effect against NB cells. The NK cell- or complement- 
mediated immune response might be more important than 
the T cell-mediated immune response because NB cells 
generally do not express HLA class I antigens. Recently, 
Pérez-Martínez et al. reported their experience using KIR 
ligand-mismatched haploidentical SCT for 3 refractory 
metastatic solid tumors, including 1 NB [5]. This approach 
was feasible, and the GVT effect was also demonstrated.
CURRENT CLINICAL TRIALS EMPLOYING RI AlloSCT
A few different clinical trials employing combinations 
of the strategies mentioned above are currently underway 
(Table 1) [6-9]. Although the number of patients enrolled 
is small and follow-up duration is short, the preliminary 
results are encouraging. However, at present, we do not 
know which is the best strategy for achieving a successful 
outcome. Further studies will yield an answer.Korean J Hematol 2012;47:3-5.
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Table 1. Clinical trials employing reduced intensity allogeneic stem cell transplantation (RI alloSCT) for neuroblastoma (NB).
Investigators Eligibility Treatment before alloSCT Stem cell source
Post-SCT 
treatment
Jubert et al. [6] Refractory/relapsed Conventional  Unrelated matched/mismatched CB  None
Sung et al. [7] Relapse after tandem autoSCT Conventional Related＞unrelated＞haploidentical None
Lang et al. [8] Relapsed Conventional Haploidentical ±DLI
Toporski et al. [4] Refractory/relapsed High-dose 
131I-MIBG tx. Haploidentical ±DLI
Pérez-Martínez et al. [5] Refractory Conventional KIR ligand mismatched haploidentical None
Lang et al.
a) Refractory/relapsed High-dose 
131I-MIBG tx. Haploidentical Anti-GD2/IL-2 
Sung et al.
a) Relapse after tandem autoSCT High-dose 
131I-MIBG tx. Related＞unrelated＞haploidentical ±IL-2
Goi et al. [9] High-risk AutoSCT Unrelated CB None
Takahashi et al.
a) Very high-risk or relapsed AutoSCT KIR ligand mismatched CB None
a)Studies are currently underway.
Abbreviations: autoSCT, autologous stem cell transplantation; MIBG, meta-iodobenzylguanidine; DLI, donor leukocyte infusion; KIR, killer cell 
immunoglobulin-like receptor; CB, cord blood.
AlloSCT FOR NEWLY DIAGNOSED HIGH-RISK NB
In the 1980s and the early 1990s, alloSCT was used as 
an alternative to autoSCT when autologous bone marrow 
had not been cleared of tumor or was impossible to harvest. 
Both the Children’s Cancer Group and the European group 
reported no difference in relapse between those treated 
with autoSCT and alloSCT, but they reported a higher toxic 
death rate in the group treated with alloSCT. Since then, 
alloSCT has been largely abandoned. However, interest in 
alloSCT has been recently renewed by successful reports 
of RI alloSCT in solid tumors, and some promising 
experimental studies demonstrated a measurable antitumor 
immune response against NB. Recently, as an alternative 
to autoSCT, a few groups have studied alloSCT in an attempt 
to harness an immunotherapeutic effect. Early studies of 
alloSCT in children with newly diagnosed high-risk NB 
suggest that it is a feasible approach that may improve 
outcome. Colleagues at Nagoya University developed a novel 
SCT protocol to treat newly diagnosed very high-risk NB 
patients; KIR ligand-mismatched cord blood SCT is given 
after autoSCT. This novel prospective study is based on 
the hypothesis that the immunological effects of alloSCT 
will be most beneficial in children with minimal tumor 
burden early in the disease process prior to relapse.
CONCLUSION
Although RI alloSCT was shown to be feasible in patients 
who failed previous treatment, alloSCT for recurrent or 
high-risk NB remains investigational, and there are still many 
issues to be resolved. Therefore, at present, alloSCT is reserved 
for specific clinical trials assessing its immunomodulatory 
effect even though the advent of RI alloSCT has provided 
the expectation that it will reduce treatment-related mor-
tality and allow for the detection of a therapeutic benefit.
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